Expression of mRNA for growth hormone-releasing hormone and splice variants of GHRH receptors in human malignant bone tumors

被引:35
作者
Busto, R
Schally, AV
Braczkowski, R
Plonowski, A
Krupa, M
Groot, K
Armatis, P
Varga, JL
机构
[1] Vet Affairs Med Ctr, Inst Endocrine Polypeptide & Canc, New Orleans, LA 70112 USA
[2] Tulane Univ, Sch Med, Dept Med, Sect Expt Med, New Orleans, LA 70112 USA
关键词
GHRH; GHRH receptors; human malignant bone tumors; autocrine growth factors; GHRH antagonists; anticancer drugs;
D O I
10.1016/S0167-0115(02)00109-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Splice variants (SV) of receptors for growth hormone-releasing hormone (GHRH) have been found in several human cancer cell lines. GHRH antagonists inhibit growth of various human cancers, including osteosarcomas and Ewing's sarcoma, xenografted into nude mice or cultured in vitro and their antiproliferative action could be mediated, in part, through these SV of GHRH receptors. In this study, we found mRNA for the SV1 isoform of GHRH receptors in human osteosarcoma line MNNG/HOS and SK-ES-1 Ewing's sarcoma line. We also detected mRNA for GHRH, which is apparently translated into the GHRH peptide and secreted by the cells, as shown by the presence of GHRH-like immunoreactivity in the conditioned media of cell cultures. In proliferation studies in vitro, the growth of SK-ES-1 and MNNG/HOS cells was dose-dependently inhibited by GHRH antagonist JV-1-38 and an antiserum against human GHRH. Our study indicates the presence of an autocrine stimulatory loop based on GHRH and SV1 of GHRH receptors in human sarcomas. The direct antiproliferative effects of GHRH antagonists on malignant bone tumors appear to be exerted through the SV1 of GHRH receptors on tumoral cells. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:47 / 53
页数:7
相关论文
共 36 条
[1]  
Benini S, 1999, INT J CANCER, V80, P581, DOI 10.1002/(SICI)1097-0215(19990209)80:4<581::AID-IJC16>3.3.CO
[2]  
2-F
[3]  
BRACZKOWSKI R, 2002, IN PRESS CANCER
[4]   Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone [J].
Chatzistamou, I ;
Schally, AV ;
Varga, JL ;
Groot, K ;
Busto, R ;
Armatis, P ;
Halmos, G .
ANTI-CANCER DRUGS, 2001, 12 (09) :761-768
[5]   Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice [J].
Chatzistamou, I ;
Schally, AV ;
Varga, JL ;
Groot, K ;
Armatis, P ;
Busto, R ;
Halmos, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (05) :2144-2152
[6]   Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro [J].
Csernus, VJ ;
Schally, AV ;
Kiaris, H ;
Armatis, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (06) :3098-3103
[7]  
Frohman L A, 1981, Prog Clin Biol Res, V74, P259
[8]   Molecular and cell biology of the growth hormone-releasing hormone receptor [J].
Gaylinn, BD .
GROWTH HORMONE & IGF RESEARCH, 1999, 9 :37-44
[9]   MOLECULAR-CLONING AND EXPRESSION OF A HUMAN ANTERIOR-PITUITARY RECEPTOR FOR GROWTH HORMONE-RELEASING HORMONE [J].
GAYLINN, BD ;
HARRISON, JK ;
ZYSK, JR ;
LYONS, CE ;
LYNCH, KR ;
THORNER, MO .
MOLECULAR ENDOCRINOLOGY, 1993, 7 (01) :77-84
[10]  
GROOT K, 1993, INT J PEPT PROT RES, V41, P162